Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aditxt Inc ADTX

Healthcare Biotechnology
Aditxt, Inc. is a biotech company focused on discovering, developing, and deploying health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc... see more

Recent & Breaking News (NDAQ:ADTX)

Aditxt Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Business Wire April 20, 2023

Aditxt Signs Asset Purchase Agreement to Acquire Fifty Percent Ownership of Global Response Aid - with Rights to Manufacture and Market Broad-Spectrum Antiviral Drug Avigan

Business Wire April 20, 2023

Aditxt Issues Shareholder Update

Business Wire April 17, 2023

Aditxt Names Media Industry Veteran Maureen Connolly as Chief Content and Engagement Officer

Business Wire March 8, 2023

Aditxt Retains Riverside Management Group as Advisor to Support Strategic M&A Driven Acquisitions by Subsidiary Pearsanta, Inc.

Business Wire March 3, 2023

Aditxt Forms its Second Subsidiary, Pearsanta, Inc., to Accelerate the Growth of its AditxtScore(TM) Program and Appoints Healthcare Executive and Current Head of AditxtScore(TM) Anthony Voorhies to Serve as its President

Business Wire February 14, 2023

Aditxt Forms Adimune, Inc. as a Wholly Owned Subsidiary with a Focus on Immune Modulation Therapies and Appoints Dr. Friedrich Kapp, Former President of the Therapeutic Business Unit at Schering AG, as its Chairman and CEO

Business Wire January 3, 2023

Aditxt's (Nasdaq: ADTX) Adimune(TM) Program Has Initiated the Manufacturing Process of Immunotherapeutic Drug Candidate, ADI(TM)-100 in Preparation for Planned Psoriasis First-in-Human Trials

Business Wire October 21, 2022

Aditxt, Inc. (Nasdaq: ADTX) Announces Development and Publication of a Mathematical Model for Predicting Longevity and Variations of Immune Response to Immunization to SARS-CoV-2 Infection

Business Wire October 12, 2022

FedEx Features AditxtScore(TM) Immune Monitoring Center and its Service in Richmond, VA, Highlighting the Importance of Quantifying Immune Health

Business Wire October 7, 2022

Aditxt, Inc. (NASDAQ: ADTX) Announces That it Has Regained Compliance with Nasdaq Listing Requirements

Business Wire September 29, 2022

Aditxt Inc. (Nasdaq: ADTX) Provides Corporate Highlights Post Reverse Stock Split and Closing of $20M Public Offering

Business Wire September 27, 2022

Aditxt Announces Closing of $20.0 Million Public Offering

Business Wire September 20, 2022

Aditxt Announces Pricing of $20.0 Million Public Offering

Business Wire September 16, 2022

Aditxt, Inc. (Nasdaq: ADTX) Announces 1-for-50 Reverse Stock Split Effective Pre-Market Opening on September 14, 2022

Business Wire September 13, 2022

Aditxt, Inc. Successfully Completes Preclinical Toxicity Study of Its Psoriasis Drug Candidate ADI(TM)-100 Advancing it Closer to First-in-Human Trials

Business Wire July 8, 2022

Premier Medical Laboratory Services Now Offering AditxtScore(TM) Personalized Immune Test for COVID-19

PR Newswire June 14, 2022

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ADTX, RCM, EXTN, ZWS

PR Newswire May 5, 2022

ADITXT INVESTOR ALERT - Kuznicki Law PLLC Investigates Aditxt, Inc. - ADTX

Business Wire May 4, 2022

Aditxt, Inc. Partners with Guthy-Renker Affiliate GRS to Launch Consumer Awareness Campaign for AditxtScore(TM) to Accelerate Adoption and Revenue Growth

Business Wire April 14, 2022